ImmunoGen (IMGN) Stock Forecast, Price & News

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

Is ImmunoGen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmunoGen stock.
View analyst ratings for ImmunoGen or view top-rated stocks.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for ImmunoGen.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, May, 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.11. The biotechnology company had revenue of $38.10 million for the quarter, compared to analyst estimates of $20.84 million. ImmunoGen had a negative net margin of 140.30% and a negative trailing twelve-month return on equity of 66.56%. The firm's revenue for the quarter was up 142.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share.
View ImmunoGen's earnings history.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75.00 million-$85.00 million, compared to the consensus revenue estimate of $84.98 million.

What price target have analysts set for IMGN?

4 brokerages have issued 1 year price targets for ImmunoGen's shares. Their forecasts range from $5.00 to $18.00. On average, they expect ImmunoGen's stock price to reach $10.25 in the next year. This suggests a possible upside of 186.3% from the stock's current price.
View analysts' price targets for ImmunoGen or view top-rated stocks among Wall Street analysts.

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the following people:

• Mr. Mark Joseph Enyedy, Pres, CEO & Director (Age 58, Pay $1.24M)
• Ms. Susan Altschuller Ph.D., Sr. VP & CFO (Age 39, Pay $537.53k)
• Dr. Anna Berkenblit M.D., MM.Sc, Sr. VP & Chief Medical Officer (Age 52, Pay $647.28k)
• Ms. Stacy A. Coen, Sr. VP & Chief Bus. Officer (Age 51, Pay $547.66k)
• Ms. Kristen Harrington-Smith, Sr. VP & Chief Commercial Officer (Age 49, Pay $562.52k)
• Ms. Renee Lentini, VP of Fin. & Principal Accounting Officer (Age 44)
• Ms. Courtney O'Konek, Sr. Director of Corp. Communications & Investor Relations
• Mr. Joseph J. Kenny, VP, Acting Gen. Counsel, Intellectual Property & Sec.
• Ms. Audrey Bergan, Sr. VP & Chief HR Officer
• Dr. Theresa G. Wingrove, Sr. VP of Regulatory Affairs & Quality (Age 64)

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen CEO Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among ImmunoGen's employees.

Who are some of ImmunoGen's key competitors?

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO) and Exelixis (EXEL).
View all of IMGN's competitors.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.86%), BlackRock Inc. (7.45%), Vanguard Group Inc. (7.02%), State Street Corp (6.22%), Wellington Management Group LLP (5.92%) and Clearbridge Investments LLC (2.50%).
View institutional ownership trends for ImmunoGen.

Which institutional investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Wellington Management Group LLP, Clearbridge Investments LLC, Goldman Sachs Group Inc., Citigroup Inc., Rhenman & Partners Asset Management AB, Principal Financial Group Inc., and Metropolitan Life Insurance Co NY.
View insider buying and selling activity for ImmunoGen or view top insider-selling stocks.

Which institutional investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Deerfield Management Company L.P. Series C, BlackRock Inc., RA Capital Management L.P., Sectoral Asset Management Inc., Granahan Investment Management LLC, Vanguard Group Inc., and UBS Group AG.
View insider buying and selling activity for ImmunoGen or or view top insider-buying stocks.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $3.58.

How much money does ImmunoGen make?

ImmunoGen has a market capitalization of $789.53 million and generates $69.86 million in revenue each year. The biotechnology company earns $-139.30 million in net income (profit) each year or ($0.600010) on an earnings per share basis.

How many employees does ImmunoGen have?

ImmunoGen employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?

The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

When was ImmunoGen founded?

ImmunoGen was founded in 1981.

What is ImmunoGen's official website?

The official website for ImmunoGen is www.immunogen.com.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at (781) 895-0600, via email at [email protected], or via fax at 781-895-0611.